Alkermes (ALKS) PEG Ratio: History & Chart

Alkermes plc(ALKS)

Drug Manufacturers - Specialty & Generic · Dublin, DU

$42.19-0.57 (-1.32%)

Delayed quote: Oct 6, 2026, 12:00 PM EDT

About Alkermes plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Dublin, DU

2,050 employees

www.alkermes.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Blair Jackson

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Alkermes plc (ALKS)	$7.08B	N/A	N/A	N/A	N/A
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.39B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.68B	N/A	2.98	2.74	2.10
Immunovant, Inc. (IMVT)vs ›	$6.66B	N/A	N/A	N/A	N/A
Hims & Hers Health, Inc. (HIMS)vs ›	$6.58B	N/A	N/A	N/A	N/A
Hinge Health, Inc. (HNGE)vs ›	$7.58B	N/A	N/A	N/A	N/A
Amneal Pharmaceuticals, Inc. (AMRX)vs ›	$6.54B	N/A	N/A	N/A	N/A
Lantheus Holdings, Inc. (LNTH)vs ›	$6.51B	N/A	0.53	0.48	0.48
HealthEquity, Inc. (HQY)vs ›	$7.66B	0.40	1.77	3.07	3.07
Cytokinetics, Incorporated (CYTK)vs ›	$7.70B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Alkermes plc (ALKS)

$7.08B

N/A

Ionis Pharmaceuticals, Inc. (IONS)vs ›

$7.39B

N/A

Chemed Corporation (CHE)vs ›

$6.68B

N/A

2.98

2.74

2.10

Immunovant, Inc. (IMVT)vs ›

$6.66B

N/A

Hims & Hers Health, Inc. (HIMS)vs ›

$6.58B

N/A

Hinge Health, Inc. (HNGE)vs ›

$7.58B

N/A

Amneal Pharmaceuticals, Inc. (AMRX)vs ›

$6.54B

N/A

Lantheus Holdings, Inc. (LNTH)vs ›

$6.51B

N/A

0.53

0.48

HealthEquity, Inc. (HQY)vs ›

$7.66B

0.40

1.77

3.07

Cytokinetics, Incorporated (CYTK)vs ›

$7.70B

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

ALKS PEG Ratio Metrics

ALKS Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics